Plasminogen kringle domains (PLG Kringles)

Plasminogen kringle domains are five homologous, triple-looped disulfide-bonded protein structures (K1-K5) located in the N-terminal region of the plasminogen zymogen (UniProt P00747). These domains are essential for the biological activity of plasminogen as they contain lysine-binding sites (LBS) that mediate the binding of plasminogen to fibrin clots and cell surface receptors (PubMed PMID: 12161288). This binding is a prerequisite for the conversion of plasminogen to the active enzyme plasmin by tissue-type plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA). In clinical practice, these domains are the primary targets for antifibrinolytic agents like tranexamic acid and aminocaproic acid, which occupy the LBS to prevent fibrinolysis and control bleeding (DrugBank DB00302). By blocking the interaction between plasminogen and fibrin, these drugs effectively stabilize blood clots in various surgical and traumatic settings (StatPearls NBK532905). Additionally, certain kringle domains, particularly K1-K3 and K4, can be proteolytically released as angiostatin, a potent inhibitor of angiogenesis that suppresses tumor growth by inducing endothelial cell apoptosis (PubMed PMID: 9548505). Research into these domains also explores their role in cell migration and inflammatory responses, where they interact with various cell-surface receptors. Thus, plasminogen kringle domains play a dual role in regulating both the vascular system's stability and the pathological progression of cancer.

Other names

Kringle domains 1-5Lysine-binding sitesLBSAngiostatin (kringle-containing fragment)

Antifibrinolytic agents competitively bind to the lysine-binding sites (LBS) within the kringle domains, particularly Kringle 1, to block plasminogen's interaction with fibrin and its subsequent activation into plasmin (DrugBank DB00302; StatPearls NBK532905).